Circulating cycloxygenase-2 in patients with tobacco-related intraoral squamous cell carcinoma and evaluation of its peptide inhibitors as potential antitumor agent
- 6 March 2010
- journal article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 136 (12) , 1795-1804
Abstract
The aim of this study was to quantitate circulating COX-2 levels in patients with tobacco-related intraoral cancer and to evaluate antitumor activities of COX-2 peptide inhibitors in vitro on KB cell lines. We used a novel biosensor-based surface plasmon resonance (SPR) technique for estimation of circulating COX-2 levels in 76 patients with oral cancer and 43 normal individuals. Antitumor activities of five COX-2 inhibitory peptides were evaluated using propidium iodide labeling and flow cytometry, alamar blue, MTS, and annexin-V binding assays. Patients with oral cancer showed threefold increase in serum COX-2 level when compared to normal controls (P < 0.0001). Further, late-stage tumors and lymph node metastasis were associated with significant increase in serum COX-2 levels. Patients with higher circulating COX-2 also showed higher immunoreactivity to anti-COX-2 antibody in the lesions. The peptides significantly reduced viability and inhibited growth/proliferation, induced cytotoxicity and apoptosis in tumor cells. However, no such effect was observed either on normal human leukocytes or on MCF-7 cell line that did not over express COX-2. Our results indicate that SPR may be a useful proteomic technique for quantitative assessment of COX-2 and to identify patients with high-risk oral premalignant or occult cancer, as well as in monitoring response to novel COX-2 targeting strategies. Furthermore, COX-2 peptide inhibitors appear to be a new class of potent anticancer agent for human oral carcinoma.Keywords
This publication has 33 references indexed in Scilit:
- Role of Cyclooxygenase-2 in Tumor Progression and Survival of Head and Neck Squamous Cell CarcinomaCancer Prevention Research, 2009
- Pilot Randomized Phase II Study of Celecoxib in Oral Premalignant LesionsClinical Cancer Research, 2008
- Cyclooxygenase-2 Expression during Immortalization and Breast Cancer ProgressionCancer Research, 2008
- Surface plasmon resonance studies and biochemical evaluation of a potent peptide inhibitor against cyclooxygenase-2 as an anti-inflammatory agentBiochemical and Biophysical Research Communications, 2007
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinomaBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2005
- Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interferenceOncogene, 2003
- Increasing incidence of oral cancer amongst young persons: what is the aetiology?Oral Oncology, 2000
- Arachidonic acid cascade and oral squamous cell carcinomaClinical Otolaryngology, 1991
- Solid Phase Peptide Synthesis. I. The Synthesis of a TetrapeptideJournal of the American Chemical Society, 1963